share_log

Sandoz Q1 Sales $2.492B Up From $2.384B YoY

Benzinga ·  May 7 15:11

Strong first quarter performance, with net sales1 of USD 2.5 billion, up 6% in constant currencies (up 5% in USD)

− Biosimilar business growing 21% in constant currencies

− All regions contributing to growth

− Acquisition of CIMERLI (ranibizumab-eqrn) completed in March 2024

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment